2006/6/30　日本経済新聞夕刊

シーメンス　バイエル診断薬買収

　独電機大手のシーメンスは２９日、医薬・化学大手バイエルの診断薬事業を買収すると発表した。金額は約４２億ユーロ(約６２００億円)。シーメンスは医療機関の検査・分析機器に強みがあるバイエルの事業買収で、ＣＴスキャンなど大型機器に注力する自社の医療機器事業を強化する。
　独禁当局の承認後、シーメンスは来年６月をめどにバイエルの事業を買収し、自社の医療機器事業に統合する。バイエルの診断薬事業の売上高は約１４億ユーロで、従業員数は約５千人。主に免疫や血液などの検査・分析機器を手掛ける。シーメンスは今月、通信インフラ機器事業で、通信機大手のノキア(フィンランド)と事業統合を決めるなど、収益事業への選択と集中を急いでいる。昨年就任したクラインフェルト社長は、医療機器を重点事業に位置づける。

2006/6/29 Siemens

Siemens to acquire Bayer Diagnostics arm
Medical Solutions Group further expands position in key high-growth molecular diagnostics market
http://www.siemens.com/index.jsp?sdc_p=fmls5uo1388841ni1079175pcz3&sdc_bcpath=1327899.s_5,&sdc_sid=17121076599&

Siemens has signed an agreement with Bayer to acquire the chemical and pharmaceutical company's Diagnostics Division. The acquisition will enable Siemens Medical Solutions (Med) to expand its position in the high-growth molecular diagnostics market. At the end of April, Siemens announced the planned acquisition of Diagnostic Products Corporation (DPC) in the U.S., a leading company in immunodiagnostics 免疫診断. The purchase price for Bayer Diagnostics - which had sales of Euro1.4 billion and a double-digit EBITDA margin in fiscal 2005 - is roughly Euro 4.2 billion.

“Demographic change is greatly increasing global demand for healthcare services and thereby generating excellent growth opportunities for Siemens,” explained Dr. Klaus Kleinfeld, Siemens President and CEO. ”The acquisition of Bayer Diagnostics is part of our targeted strategy to create the healthcare industry's first integrated diagnostics company by combining the entire imaging diagnostics, laboratory diagnostics and clinical IT value chain under one roof.” Kleinfeld also noted that this acquisition, which is subject to regulatory approval, is - like other purchases in the last few quarters - further proof that Siemens is rigorously focusing its portfolio on promising growth fields.

Dr. Erich R. Reinhardt, member of the Siemens Managing Board and President of Siemens’ Medical Solutions Group, commented: “Molecular medicine is becoming increasingly important since it enables healthcare professionals to identify the causes of disease using genetic profiles. With the help of molecular medicine, it will be possible not only to predict the effects of the medications selected and tailor treatment for individual patients, but also to diagnose disease at an early stage. The planned acquisition of DPC has provided us with access to laboratory diagnostics. With the acquisition of Bayer Diagnostics, we will now have a comprehensive portfolio in this key future-oriented market. These deals will enable us to considerably expand our range of expertise and further our leading position as a trendsetter in healthcare.”

The two acquisitions will make Siemens Medical Solutions No. 2 worldwide in immunodiagnostics. In addition, the acquisition of the Bayer unit will enable the Siemens Group to tap the rapidly growing market for molecular diagnostics based on gene analysis (nucleid acid testing). Bayer Diagnostics is also a world market-leader in clinical chemistry with a leading position in near-patient testing, laboratory automation and hematology (blood cell diagnostics).

“We are convinced that the successful laboratory equipment business has even better prospects in a company specializing in medical technology. The decision to divest our Diagnostics Division is fully in line with our strategy for systematically aligning our healthcare business. We are concentrating on pharmaceuticals for both humans and animals, and products that can be promoted directly to patients,” commented Bayer AG Management Board Chairman Werner Wenning.

Siemens Medical Solutions develops products and services that improve recovery rates by diagnosing diseases earlier and more accurately. Its goal is to enable its customers to increase healthcare quality while improving efficiency. Siemens is an innovations driver in diagnostic imaging systems (in-vivo diagnostics) and the market leader in healthcare IT. The company strengthened its position in molecular in-vivo diagnostics last year through the acquisition of CTI, delivering increased capabilities in the development and manufacture of positron emission tomography (PET) systems that can be used, for example, in the diagnosis of cancer and Alzheimer's disease, in addition to advanced development of new molecular contrast agents and pharmaceutical tracers.

The acquisitions of DPC and Bayer Diagnostics are expected to fuel further innovations that will considerably improve the quality of healthcare through early, specific and efficient diagnostic solutions.

Sales of Bayer Diagnostics rose in 2005 by 8.4 percent to EUR 1.4 billion. It offers an extensive portfolio of in-vitro diagnostic products for evaluating and monitoring the therapy of numerous diseases, including cardiovascular disorders, kidney diseases, infections, cancer and diabetes. The business units are Laboratory Testing, including the ADVIA CentaurR and CentaurR CP, ADVIAR Clinical Chemistry, ADVIA LabCellR and WorkCellR Automation, ADVIAR Hematology and ClinitekR Atlas systems; Near Patient Testing, with its RapidpointR, RapidlabR, RapidComm? and ClinitekR brands; and Molecular Testing, with its TrugeneR and VersantR lines of tests and systems.

Siemens Medical Solutions (Med) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. From imaging systems for diagnosis, to therapy equipment for treatment, to patient monitors to hearing instruments and beyond, Siemens innovations contribute to the health and well-being of people across the globe, while improving operational efficiencies and optimizing workflow in hospitals, clinics, home health agencies, and doctors' offices. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of ?7.6 billion, orders of ?8.6 billion and Group profit of ?976 million for fiscal 2005 (September 30). Further information is available at: www.siemens.com/medical.

A Siemens press conference will be held in Munich on June 30, 2006, at 10:00 a.m. (CEST) on the acquisition of Bayer Diagnostics by Siemens Medical Solutions. Dr. Klaus Kleinfeld, CEO of Siemens AG, and Prof. Dr. Erich Reinhardt, Group President of Siemens Medical Solutions, will host the conference. The telephone transmission (listen only) of this conference can be heard at the dial-in numbers +49 89 2030 3244 (in German) and +49 89 2030 3242 (English) or on the Internet via audio streaming at: www.siemens.com/press. Please dial in at latest 15 minutes before the press conference begins. A recording of the conference will be available on the Internet immediately afterwards.

January 1, 2007

Acquisition of Bayer's Diagnostic Division Finalized:
New Business - "Siemens Medical Solutions Diagnostics" - founded in the United States

The acquisition of Bayer Healthcare's diagnostic division by Siemens Medical Solutions has been completed. Bayer Diagnostics and Diagnostic Products Corporation (DPC), acquired in July 2006, were merged into a single business unit on January 1, 2007. The new entity, "Siemens Medical Solutions Diagnostics," is a wholly owned subsidiary of Siemens Medical Solutions USA, Inc. and employs more than 8,000 people worldwide. Siemens Medical Solutions Diagnostics, headquartered in Tarrytown, N.Y. and Los Angeles, CA, holds a No. 2 position in the worldwide immunodiagnostics market.

This new business is integral to Siemens' overall strategy to help its customers improve workflow throughout the healthcare enterprise. Bringing together the entire medical imaging, laboratory diagnostics and clinical IT value chain under one roof puts Siemens in a unique position to leverage trendsetting technologies for an improved quality of patient care at reduced costs.DPC and Bayer Diagnostics generated cumulative sales of ?1.8 billion in fiscal 2005 (Dec. 31). The cost for both acquisitions totaled ?5.7 billion.

"With the acquisitions of DPC and Bayer Diagnostics, we invested heavily in a future oriented and growing market in the health care sector. We see tremendous potential for Siemens Medical Solutions Diagnostics and have high expectations for the new unit," said Klaus Kleinfeld, CEO of Siemens AG.

"Siemens is the world's only full-service diagnostics company ? bringing together for the first time a unique set of products and services that will speed the development of molecular medicine capabilities, and improve the efficiency and quality of healthcare," said Erich Reinhardt, Ph.D., member of the Managing Board of Siemens AG and president and CEO of Siemens Medical Solutions. "Siemens has anticipated the convergence of social, economic and political challenges facing the healthcare industry, and we alone have responded and developed this comprehensive portfolio of innovative solutions, from medical imaging and healthcare information technology (IT), to management consulting and, now, laboratory diagnostics," Reinhardt added.

Siemens Medical Solutions Diagnostics maintains leading market positions in the fields of clinical chemistry, patient tests, laboratory automation and blood cell diagnostics (hematology). The company also develops solutions for the rapidly growing markets of molecular diagnostics and gene analysis with the aim of continuing to improve personalized medicine. The company will also offer a comprehensive portfolio for the diagnosis and treatment of a wide array of illnesses such as adrenal/pituitary dysfunction, allergy, anemia, diabetes and reproductive and thyroid disorders, infectious diseases, kidney ailments, cardiology, oncology, diabetes and virology.

Siemens Medical Solutions Diagnostics' top management is comprised of managers with many years' experience in the health care business: Anthony Bihl, previous president of the Diagnostics division of Bayer Healthcare LLC, has been named as CEO. Sid Aroesty, who served as president and COO of DPC, was nominated COO of the new business; and Jochen Schmitz, previous CFO of the Siemens Medical Solutions Molecular Imaging division, will assume the CFO role.

"At Siemens, our people are one of our most important assets," explained Reinhardt. "The combined business expertise and industry knowledge of this team will help us ensure that product and service innovation continues, customers are well served, and business success is achieved."

Siemens (Berlin and Munich) is a global powerhouse in electrical engineering and electronics. The company has around 475,000 employees working to develop and manufacture products, design and install complex systems and projects, and tailor a wide range of services for individual requirements. Siemens provides innovative technologies and comprehensive know-how to benefit customers in over 190 countries. Founded more than 155 years ago, the company focuses on the areas of Information and Communications, Automation and Control, Power, Transportation, Medical, and Lighting. In fiscal 2006 (ended September 30), Siemens had sales from continuing operations of ?87.3 billion and net income of ?3.033 billion.
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics ? such as Diagnostic Products Corporation and Bayer Diagnostics ? mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30).

2006/4

Siemens to acquire Diagnostic Products Corporation
Siemens Medical Solutions enters the in-vitro diagnostics market
http://www.medical.siemens.com/webapp/wcs/stores/servlet/PressReleaseView?storeId=10001&langId=-11&catalogId=-11&catTree=100005,13839,17709&pageId=74203

Siemens and Diagnostic Products Corporation (DPC) announced today that they have entered into a merger agreement under which Siemens will acquire DPC for approximately $1.86 billion. DPC is one of the global leaders in immunodiagnostics, focusing on developing, manufacturing and distributing automated body fluid analyzers and tests, such as those related to cancer and cardiac disease, as well as hormone and allergy conditions. Through its presence in more than 100 countries, DPC offers comprehensive immunodiagnostic solutions to hospitals, clinics and laboratories across the globe.
In the merger, each shareholder of DPC will receive $58.50 (in cash) per share for each share of DPC stock then held, and DPC will become a wholly owned subsidiary of Siemens Medical Solutions USA, Inc. The completion of the merger is subject to approval by DPCbs shareholders, receipt of regulatory approvals and other customary closing conditions. The parties anticipate that the shareholdersb meeting will be held in mid 2006. The board of Directors of each company have approved the agreement.
Through this acquisition, Siemens Medical Solutions intends to expand its existing healthcare solutions portfolio and further the companybs objective to enable early and specific diagnosis and individualized patient therapy. Siemens bridges the gap between in-vivo and in-vitro diagnostics and brings together a unique blend of expertise and technologies in diagnostic imaging, healthcare information technology (IT), molecular biology and biochemistry to drive and lead the advancement of personalized healthcare across the globe. The acquisition of DPC is a major milestone in the development of integrated, clinical workflow-oriented solutions that will improve the quality while increasing the efficiency of patient care.
bWe are impressed by DPCbs track record in developing a globally leading immunodiagnostics business and by the quality of its people. The potential is huge to drive ground-breaking innovations by combining DPCbs in-vitro diagnostics leadership with Siemensb leading position in medical imaging and healthcare IT solutions,b said Erich R. Reinhardt, president and CEO of Siemens Medical Solutions of Siemens AG (NYSE: SI). bTogether, both companies will be empowered to continue to revolutionize the prevention, diagnosis, treatment and management of disease.b
Founded in 1971, DPC is the world's leading independent producer of immunodiagnostic products. The companybs diagnostic tests supply information vital to the detection and management of disease, including adrenal/pituitary dysfunction, allergy, anemia, bone metabolism disturbances, cancer, cardiovascular disease, diabetes and reproductive and thyroid disorders.
bWe believe that this merger with Siemens will be a very positive development for the future of our employees, customers and the company as a whole. This merger will allow us to continue on our current rapid course of development while also providing DPC access to the resources and support of a recognized leader in the delivery of integrated healthcare solutions,b said Michael Ziering, CEO of DPC. bSiemens Medical Solutions is a perfect match for DPC in terms of corporate philosophy, business practice and future direction,b added Ziering.
Siemens Medical Solutions is one of the worldbs largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. From imaging systems for diagnosis, to therapy equipment for treatment, to patient monitors to hearing instruments and beyond, Siemens innovations contribute to the health and well-being of people across the globe, while improving operational efficiencies and optimizing workflow in hospitals, clinics, home health agencies, and doctors' offices. Employing approximately 33.000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and group profit of 1 billion EUR for fiscal 2005. Further information can be found under: http://www.siemens.com/medical

Diagnostic Products Corporation, founded in 1971, is a leader in the global in vitro diagnostics market. DPCbs product offering includes the widely accepted IMMULITEB. series of immunoassay systems, more than 75 immunoassays and an expanding menu of essential specific allergens and allergy panels that are run just like other immunoassays. DPC also designs and manufactures automated laboratory instrumentation and automation solutions that provide fast, accurate results while enabling our customers to do "more with less" in a leaner laboratory. DPCbs combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. In fiscal 2005 (December 31), DPC reported sales of $481 million and income from operations of $96 million. Additional information can be found at DPCbs website at www.dpcweb.com

2005/3/15

Siemens To Acquire CTI Molecular Imaging, Inc.
Acquisition Expands Molecular Imaging Competencies of Siemens Medical Solutions - Joint Press Release by Siemens und CTI Molecular Imaging

Siemens and CTI Molecular Imaging, Inc. (Nasdaq: CTMI) announced today that they have entered into a merger agreement under which Siemens will acquire CTI. The acquisition will include all the businesses of CTI Molecular Imaging, Inc., including CTI PET Systems, PETNET Solutions, CTI Mirada Solutions, CTI Molecular Technologies and CTI Concorde Microsystems. Under the terms of the agreement, Siemens Medical Solutions USA, Inc., will commence a cash tender offer within ten business days to acquire all of the outstanding shares of CTI stock at a price of $20.50 per share. Following the completion of the tender offer, any remaining shares of CTI stock will be acquired in a merger at the same price per share. The board of directors of each company has approved the agreement. The transaction is subject to customary regulatory approvals and other customary closing conditions, and is expected to close in the second quarter of 2005. The transaction has a value of approximately $1 billion.

With this acquisition, Siemens Medical Solutions continues and strengthens its commitment to molecular imaging development, technological innovation and the creation of dynamic new technologies that will revolutionize the diagnosis and treatment of disease.

“This step is a natural progression in our long-time association with CTI, and reflects Siemens’ overall strategy to transform the delivery of healthcare by developing trendsetting innovations that improve patient care while reducing costs,” said Erich Reinhardt, Ph.D., president and CEO, Siemens Medical Solutions.

CTI Molecular Imaging was established in 1983, focusing on positron emission tomography (PET) and molecular imaging and later extended its business into research, development and the distribution of PET tracers and probes. CTI PET Systems (CPS) was formed in 1987 as a joint venture between CTI and Siemens to combine CTI’s expertise in PET technology with Siemens’ global distribution network.

Michael Reitermann, president of Siemens Medical Solutions Nuclear Medicine Division, commented, “Molecular medicine will result in more individualized and more effective diagnosis and therapy. CTI Molecular Imaging has been actively engaged in next-generation molecular diagnostics research and the development of new imaging technologies and biomarkers. This acquisition will enable Siemens to strengthen and broaden our capabilities in molecular imaging, and define new standards within the industry.”

“This acquisition represents the combination of two companies that are innovation leaders. It will benefit PET imaging’s continued advancement as well as enhance the future of molecular imaging,” added Ronald Nutt, Ph.D., president and CEO of CTI Molecular Imaging.

Siemens Medical Solutions of Siemens AG (NYSE: SI) with headquarters in Malvern, Pennsylvania and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.07 billion EUR, orders of 8.12 billion EUR and group profit of 1.05 billion EUR for fiscal 2004. More information can be obtained at http://www.usa.siemens.com/medical-pressroom.

CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology for detection and treatment of cancer, neurological disorders and cardiac disease. In fiscal year 2004 (September 30), CTI reported sales of $402 million and income from operations of $58 million. Additional information is available at http://www.ctimi.com.

About PET and PET/CT:
PET images the biology of diseases at the molecular level, often before anatomic changes are visible or, in some cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT is an imaging technology that combines the biological examination of patients by PET with the CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians with precise anatomical landmarks associated with the disease condition as determined by PET. PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.

2006年6月19日

ノキアとシーメンス、コミュニケーション・サービス・プロバイダー事業を統合 - 固定・モバイル コンバージェンスの新しいグローバル ネットワークリーダーに

ノキアとシーメンスは本日、ノキアのネットワークス事業部とシーメンスのキャリア関連ビジネスを新会社に統合し、ノキア・シーメンス・ネットワークス（Nokia Siemens Networks）という名称の下に新会社を設立すると発表しました。新会社は50-50の出資比率の合弁会社で、固定およびモバイル・ネットワーク・インフラストラクチャとサービスの重要な成長分野において、確固たる地位を持つグローバル・リーダー企業を生み出すものです。

この合弁会社はその規模とグローバルな拠点展開により、売上生成とコスト効果の高い製品やサービスを開発及び販売していくことになります。ノキア・シーメンス・ネットワークスはまた次世代の固定およびモバイル・プラットフォームとサービス分野への投資を行える、世界最高レベルの研究開発チームのひとつを持つことになります。さらに新会社は世界クラスのFMC（固定・モバイル・コンバージェンス）の能力と相互に補完可能なグローバルな顧客ベースを持ち、先進市場と新興市場両方における確固とした地位、そして業界最大且つ最も豊富な経験を持つサービス組織を持つことになります。

ノキアのCEOであるオリペッカ・カラスブオは次のように述べています。「シーメンスとの提携は、世界市場で競争し、株主価値を創出するために必要な規模と幅広い製品ポートフォリオを構築する最も効果的な手段だと確信しています。コミュニケーション産業は融合が進んでおり、強力且つ独立したノキア・シーメンス・ネットワークスは、お客様のコスト削減と売上拡大を支援し、同時にコンバージェンス技術の課題に取り組んでいく上で理想的な位置付けにあります。」

オリペッカ・カラスブオはノキア・シーメンス・ネットワークスの会長に就任する予定です。

シーメンスのCEO、クラウス・クラインフェルトは次のように述べています。「この合弁は、市場における地位を持続可能な形で強化するための第一歩であり、最先端のコンバージェンス技術とサービスをお客様に提供することを可能にします。両社が力を合わせることによって極めて強く、大きな成長力を持ち、将来の利益性を改善でき準備が整った、業界をリードする企業が生まれます。」

規模とコンバージェンス・ポートフォリオを持つ強力なプレイヤー

2005年暦年ベースの新会社の仮年間売上高は158億ユーロ規模で、同社発足時の社員数は6万人となる予定です。現在のマーケットシェアデータによると、モバイル・インフラストラクチャの分野では世界第2位、サービスで第2位、固定ネットワークでは第3位、そしてテレコミュニケーション全体のマーケットでは第3位になる予定です。

ノキア・シーメンス・ネットワークスは、通信事業者に対して、固定・モバイルネットワーク製品の包括的なポートフォリオとそれらをサポートするプロフェッショナル・サービスの提供ができるようになります。同社のポートフォリオには、IMS(IP Multimedia Subsystem）のような次世代ネットワーク・コンバージェンス製品、2G GSM/EDGEアクセス (Enhanced Data rates for GSM/Evolution)、3G WCDMA/HSDPA アクセス (Wideband Code Division Multiple Access/High Speed Downlink Packet Access)、広範なモバイル・コア、固定ブロードバンド、トランスポート、IPTV (Internet Protocol Television)、LTE (Long Term Evolution)、WiMAX(Worldwide Interoperability for Microwave Access) から新興市場向けの低価格のモバイル音声製品が含まれます。

広範なシナジー効果
2010年までに年間15億ユーロと推定されているコストシナジー効果は、主に両社にて重複する部門の廃止、営業・マーケティング組織の統合と活用、間接費の削減、調達面でのメリット、R&Dでの効率改善から発生すると予想されています。

これらのシナジーの相当部分は、最初の2年間に発生すると予想されています。設立当初の6万人の従業員数は、4年間で10〜15％の範囲での調整が行われる予定です。人員削減のアセスメントは統合計画の一部として、従業員側代表との協議が必要となります。

この提携によるそれぞれのEPS（１株利益）への影響については、ノキアとシーメンスの両社とも、2007年1月1日に締結が完了したものとして、リストラ費用を除いた暫定ベースにおいて2007年末までの時点でプラスになると予想しています。

グローバルカンパニーとリーダーシップ
ノキア・シーメンス・ネットワークスは本社をフィンランド・ヘルシンキに置き、ドイツ・ミュンヘンに強力な地域本社を持つ予定で、新会社の5つの事業部のうち3つはミュンヘンを拠点とする予定です。

現在ノキアのネットワークス事業部の上級副社長兼ジェネラル・マネージャーであるサイモン ベレスフォード ワイリーが合併後直ちに新会社の最高経営責任者（CEO）に就任します。

「ノキア・シーメンス・ネットワークスは、これまでにない変革が業界に起こっている時期に、コミュニケーション産業で最もすばらしい2つのチームが結集します。私はノキアの力を十分に知っており、また、シーメンスの人々の質と精神に深い敬意を抱いています。ノキアとシーメンスが力を合わせたチームは業界における地強い勢力として、比類ない顧客満足度を提供し、明らかな業界リーダーになるという目標を追及していきます。」とサイモン・ベレスフォード ワイリーは述べています。

またペーター・シェーンホーファー（Peter Schoenhofer）はCFOに就任します。シェーンホーファーは、現在シーメンスAGオーストリアの役員です。

この移管は2007年１月１日までに完了を予定しており、関係当局による許認可、締結に必要な標準的な条件、一連の詳細な実施手続きについての合意が前提条件となります。法的締結完了後は、ノキア・シーメンス・ネットワークスの業績はノキアの連結決算の一部となり、シーメンスは持分比率に応じて計上します。

シーメンスについて
シーメンス（本社ベルリン/ミュンヘン）は、電機・電子分野におけるグローバル企業です。従業員数461,000人を擁し、製品開発、製造、複合的なシステムとプロジェクトの設計と工事、個々のお客様の要望に応じた広範なサービスを提供しています。また、シーメンスは190カ国のお客様の利益のために革新的な技術と包括的なノウハウを供給しています。創立は1847年に遡り、現在、情報通信、オートメーション＆コントロール、電力、交通、医療、照明を主要な分野として活動しています。2005年度（9月30日期）、シーメンスの売上高は754億ユーロ、継続事業からの営業利益は30億5800万ユーロでした。

ノキアについて
ノキアは、広範囲にわたって携帯通信業界の持続可能な発展に常に取り組んでいる、モバイル・コミュニケーションで世界をリードする企業です。ノキアは、携帯電話をはじめ、イメージング、ゲーム、メディア、ビジネス向けのデバイスやソリューションといった使いやすく革新的な製品を通じて、人と人、そして人と情報を結んでいます。また、ネットワーク通信事業者や企業向けの機器、ソリューションおよびサービスも提供しています。

Jul 25, 2007 Siemens

Siemens to acquire Dade Behring
　　Medical Solutions Group becomes leader in the growing Diagnostics Market

Siemens has signed a merger agreement with US-based Dade Behring, Inc., a leading clinical laboratory diagnostics company. Siemens intends to acquire all outstanding shares of Dade Behring by submitting a cash offer to the Dade Behring shareholders of US$77 per common share. The planned acquisition has a total transaction volume of approximately US$7 billion (roughly Euro 5 billion). Closing is expected in the second quarter of fiscal year 2008. Completion of the merger is subject to receipt of regulatory approvals and other customary closing conditions.

Dade Behring, headquartered in Deerfield, Illinois, has operations in 35 countries and serves more than 25,000 customers around the world. The company provides clinical laboratory equipment and integrated solutions for routine chemistry testing, immunodiagnostics (including infectious disease testing), hemostasis testing and microbiology. With its approximately 6,400 employees, Dade Behring realized sales of approx. US$1.7 billion in fiscal year 2006 and an EBIT of US$201 million including US$21 million restructuring expense.

"Demographic changes and increasing demand for higher quality healthcare systems represent a constant driver for growth in this sector," stated Peter Löscher, Chief Executive Officer of Siemens AG. "Complementing last year's acquisitions of Diagnostic Products Corporation and Bayer Diagnostics, this transaction secures our leading position in the highly attractive healthcare industry. The impact of the Dade Behring acquisition on Siemens EPS (Earnings Per Share) is expected to be accretive from fiscal year 2010."

Erich R. Reinhardt, member of the Managing Board of Siemens AG and President of Siemens Medical Solutions added: "The acquisition of Dade Behring will create significant value for our shareholders. It will strengthen Siemens' position in the highly profitable and high-growth healthcare sector." The acquisition is expected to increase Siemens Medical Solutions Group's margin from 2009 onwards.

By further strengthening its presence in clinical laboratory diagnostics, Siemens Medical Solutions continues to pursue its vision to become the global leader in full-service diagnostics, offering imaging diagnostics, clinical laboratory diagnostics and healthcare IT solutions - from a single source and along the entire value chain. "The planned acquisition of Dade Behring complements our current capabilities and offers us the unique opportunity to create an unparalleled portfolio of products and services, and become world market leader in comprehensive clinical laboratory diagnostics," highlighted Erich R. Reinhardt.

"Together, Dade Behring and Siemens will become uniquely positioned to offer the broadest and most capable range of clinical diagnostic products and services in the world," said Jim Reid-Anderson, Dade Behring's Chairman, President and CEO. "I am confident that this is the right decision for our company and I am convinced that this next stage for Dade Behring will be both exciting and rewarding as we set a new standard for being part of the world's first full service diagnostic company."

Siemens (Berlin and Munich) is a global powerhouse in electrical engineering and electronics. The company has around 475,000 employees (incl. discontinued operations) working to develop and manufacture products, design and install complex systems and projects, and tailor a wide range of services for individual requirements. Siemens provides innovative technologies and comprehensive know-how to benefit customers in over 190 countries. Founded more than 160 years ago, the company focuses on the areas of Information and Communications, Automation and Control, Power, Transportation, Medical, and Lighting. In fiscal 2006 (ended September 30), Siemens had sales of Euro 87.3 billion and net income of Euro 3.033 billion, according to U.S. GAAP. Further information is available on the Internet at: www.siemens.com

Siemens Medical Solutions of Siemens AG is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics ? such as Diagnostic Products Corporation and Bayer Diagnostics ? mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of ?8.23 billion, orders of ?9.33 billion and group profit of ?1.06 billion for fiscal 2006 (Sept. 30), according to U.S. GAAP. Further information can be found by visiting www.siemens.com/medical.

About Dade Behring, Inc.
With 2006 revenue of more than US$1.7 billion, Dade Behring offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com.

---

Jul 25, 2007 Siemens

Siemens sells automobile supplier business to Continental for Euro11.4 billion

Siemens AG is signing an agreement with Continental AG, Hanover, Germany, to sell its entire stake in Siemens VDO Automotive AG (SV). The price is Euro11.4 billion. The closing of the transaction is subject to approval by the responsible antitrust authorities and other closing conditions and is expected in the current calendar year. Peter Löscher, President and CEO of Siemens AG, said: "We have reached an outstanding result. We have carefully evaluated all options for SV and chose the best perspectives for the employees, customers, and our investors." Preparations for the planned IPO of SV will be terminated.

The sale of SV supports the goals set in the company’s Fitfor 2010 program. These goals include a focused further development of the business portfolio in the three application fields of Energy and Environmental Care, Automation and Control/Industrial and Public Infrastructures, and Healthcare. “We have already made major investments in these fields in the recent past,” commented Löscher. “As we pursue this course, we must be even more oriented to growth and margins, and keep an eye on the capital-intensity of our businesses. We will make Siemens more focused, less complex, and faster.”

The predecessor of SV, Siemens Automotive Systems (AT), was established around 20 years ago. The business developed rapidly and marked a major milestone when it merged with Mannesmann VDO in 2001. In fiscal 2006, SV had sales of roughly Euro10 billion and employed some 53,000 people at around 130 locations worldwide, including about 19,600 in Germany. Wolfgang Dehen, President of SV, said: “All employees can be proud of what we as a team have achieved with SV so far. The new product portfolio, clearly focused on the growth field of automotive electronics, will offer great possibilities for the future.”

Siemens VDO Automotive AG, a Group of Siemens AG, is one of the world's leading suppliers of electronics and mechatronics for the automotive industry. With its products, it enables individual mobility and the efficient transportation of goods by road in modern societies. As development partner of the automotive industry, the company manufactures automotive electronics and mechatronics for reducing emissions, enhancing safety and driving comfort, and keeping drivers informed and in touch with the outside world. Siemens VDO generated sales of over Euro10 billion in fiscal year 2006 (to September 30) and Group profit of ?669 million (based on US GAAP).

　

.